Abstract Activation of Akt signaling pathway has been documented in various human malignancies, including breast carcinoma. The objective of this study is to determine the incidence of Akt phosphorylation in breast tumours and its relationship with expression of ER-α, ER-β, HER2, Ki-67 and phosphorylated Bcl-2 associated death domain (p-BAD). Immunohistochemical staining was performed to detect these molecules on 43 paraffin-embedded breast tumour tissues with commercially available antibodies. Eighteen
Introduction
Breast cancer affects woman worldwide and in Malaysia, it is the most frequent type of cancer in females [1] . The presence of oestrogen receptor (ER)-α in breast tumours is used clinically to predict the likelihood of response to hormonal therapies. However, even though it has been reported that the response rate is >70% in ER positive cases [2] with >40% of these patients will eventually develop resistance [3] . Drug resistance problems have also been reported for trastuzumab, a monoclonal antibody which targets the human epidermal growth factor receptor 2 (HER2) [4] . A number of reasons for drug resistance have been proposed including the hyperactivation of Akt/protein kinase B (PKB). High phosphorylated Akt (p-Akt) level has been associated with tamoxifen-resistant breast cancer patients [5] . Akt has also been shown to contribute to chemoresistance and radioresistance in non-small lung cancer and breast cancer cell lines [6, 7] . This suggests that inhibition of Akt activity may be a useful strategy to overcome chemoresistance. Thus, potent and selective inhibitors targeting Akt are potentially promising drug candidates for hormone insensitive or chemoresistant tumours. An inhibitor of Akt has been shown to inhibit the growth of tumours [8] . Perifosine, an Akt inhibitor, is currently being evaluated in a multitude of Phase I and II studies [9] .
Akt1 is a serine/threonine protein kinase that was first discovered as the human homologue of the transforming gene of an oncogenic virus [10, 11] . Two additional isoforms, Akt2 and Akt3 have been identified and all three isoforms have transforming ability [12, 13] . Akt is a downstream target of signaling pathways stimulated by various receptors such as HER2 and insulin-like growth factor 1 receptor. In vitro studies show that activation of Akt by growth factors depends on the binding of phosphoinositide-3,4,5-triphosphate (PIP3) and the phosphorylation of Akt at Ser473 and Thr308. Phosphorylation of both sites is necessary for full activity of Akt in vitro. Distinct enzymes are responsible for the phosphorylation of Akt, for example, phosphoinositide-dependent kinase 1 (PDK-1) phosphorylates Akt at threonine residue 308 [14, 15] and rictor-mTOR is responsible for Ser473 phosphorylation [16, 17] . P-Akt is a powerful promoter of cell survival as it antagonises the components of the apoptotic cascade such as the Bcl-2 associated death domain (BAD) protein. Akt is also implicated in angiogenesis and metastasis which are the two important processes in cancer development [18, 19] . Thus, it is not surprising that frequent activation of Akt occurs in a wide spectrum of cancers such as prostate, breast and ovarian carcinomas [20] . In addition, HER2-overexpressing tumour with high p-Akt expression has been associated with poor disease survival [21] . However, majority of these studies used antibodies against p-Akt (Ser473) but not p-Akt (Thr308). It is unknown whether the phosphorylation of Akt at Ser473 and Thr308 occurs equally in the same tumour.
The applications of molecular-targeted therapies such as Akt inhibitors require clinical trials such as exemplified by tamoxifen, trastuzumab and gefitinib (an inhibitor of epidermal growth factor receptor). A systematic examination of ER-α, HER2 and signal transduction proteins such as Akt in primary breast tumour tissues is required as a prelude to clinical studies to assess the efficacy of Akt inhibitors in patients. Thus, the objectives of this study were, firstly, to determine the frequency of p-Akt (Ser473), p-Akt (Thr308), ER-α, ER-β, HER2, p-BAD, and Ki-67 expression and their relationships in breast tumour tissues, and secondly, to investigate the association of these biomolecules with the clinicopathological features of tumour. We also examined the ER-β expression since it has been suggested that loss of ER-β expression could be one of the events leading to breast cancer development [22] . Moreover, its frequency in breast tumours in Malaysia is still unknown. We are also aware about the significance of progesterone receptor expression but this was not elucidated in our endeavors for identifying molecular targets.
Materials and Methods

Tissue Specimens
A total of 43 surgically resected breast cancer specimens were retrieved from archived clinical material collected between 1999 and 2002. Ethics approval was obtained from the institutional ethics review committee. Demographics of the 43 samples used for this study are summarised in Table 1 
Immunohistochemical Staining
Immunohistochemistry was performed by the standard biotin-streptavidin-peroxidase method on 4 μm-thick formalin-fixed, paraffin-embedded tissue sections. After deparaffinization in xylene and rehydration in descending concentrations of alcohol, an antigen retrieval step was performed by microwaving in 10 mM citrate buffer (pH 6) for 20 min at boiling temperature. Endogenous peroxidase was blocked by 3% hydrogen peroxide. After blocking with 3% bovine serum albumin for 1 h, the sections were incubated with the diluted primary antibody for appropriate time, as listed in Table 2 . The immunoreactivity was detected by using LSAB+ Kit (Dako, Carpinteria, CA) in room temperature according to the manufacture's instructions. The 3,3′-diaminobenzidine (DAB) (Liquid DAB+; Dako, Carpinteria, CA) solution was used as a chromogen. Sections were lightly counterstained with hematoxylin. The section without primary antibody served as negative control.
Evaluation of Immunohistochemical Staining
Immunostained tissue sections were evaluated under ×200 magnification by light microscopy. A total of 5-10 fields were viewed and scored. A modified semi-quantitative scoring system adopted from previous studies [23, 24] was used to evaluate the immunoreactivity of p-Akt (Thr308), p-Akt (Ser473), p-BAD (Ser136), and Ki-67. The score for percentage of positive cells was assigned using the following scales: 0, no staining of cells in any field; 1, <25%; 2, 25-50%; 3, 50-75%; 4, >75%. The intensity of staining was scored using the following scales: 1+, mild staining; 2+, moderate staining; 3+, strong staining. The final total score was obtained by the sum of the score for percentage of positive cells and the score of staining intensity. Hence, the possible total scores were 0 and 2-7.
For assessment of the positivity, total scores of ≥3 were considered positive. The Allred scoring system [25] was used to determine the positivity of ER-α and ER-β. Briefly, a proportion score was assigned representing the estimated proportion of positive staining tumor cells (0, none; 1, >0 to 1/100; 2, >1/100 to 1/10; 3, >1/10 to 1/3; 4, >1/3 to 2/3; 5, >2/3 to 1). An intensity score was also assigned, which represented the estimated average staining intensity of positive tumour cells (0, none; 1, weak; 2, intermediate; 3, strong). The proportion score and intensity score were then added to obtain a total score (0 or 2-8). A positive result for both ER-α and ER-β was defined as total score ≥3.
HER2 immunoreactivity was scored according to the criteria specified by Dako for the interpretation of the HercepTest [26] . Immunoreaction was determined as positive if more than 10% of the tumour cells showed weak to moderate complete membrane staining (2+) or strong complete membrane staining (3+). All other staining patterns were interpreted as negative (0, no staining; 1+, a faint and incomplete membrane staining was detected in more than 10% of the tumour cells).
Statistical Analysis
The total scores of immunostaining were used to perform the statistical analysis. The association of biomolecules with clinicopathological variables was performed by the Mann-Whitney U-test or Kruskal-Wallis one-way analysis of variance by ranks. Spearman rank correlation test was used to assess the correlation among the expression of biomolecules. A 2-sided p value of less than 0.05 was considered statistically significant. Statistical analysis was performed by using SPSS 11.5 statistical software.
Results
Analysis of ER-α, ER-β, HER2, p-Akt (Ser473), p-Akt (Thr308), p-BAD (Ser136), and Ki-67 Immunoreactivity
The case distribution of the various biomolecules according to their immunohistochemical score is shown in Fig. 1 . Positive nuclear ER-α, ER-β and membranous HER2 immunoreactivity (Fig. 2a-c) was observed in 18/43 (41.9%), 3/43 (7.0%), and 23/43 (53.5%) breast tumour tissues, respectively (Fig. 1a-c) . Comparison of positive ER-α and ER-β scores showed that ER-β scores were lower (score 3-4), compared to that of ER-α (score 3-8). ER-α and ER-β were expressed by 3/13 (23.1%) and 7/13 (53.8%) apparently normal adjacent breast tissues, respectively (data not shown). All of the apparently normal adjacent breast tissues (13/13; 100%) did not express HER2 (data not shown). There was definitely a larger proportion (Fig. 1d,e) . The positive immunohistochemical scores of the cytonuclear staining (Fig. 2d ,e) were similar for both phosphorylation sites (score 5-7). Positive cytoplasmic p-BAD (Ser136) and nuclear Ki-67 immunoreactivities (Fig. 2f,g ) were observed in 29/43 (67.4%) and 34/42 (81.0%) breast tumour tissues, respectively (Fig. 1f,g ). Majority of p-BAD (Ser136)-positive cases had a score 5 (20/43) . Eight samples had a score 6 and one sample had the highest score. As for the Ki-67 staining, majority of the immunopositive tumour tissues had a score 4 (19/42). (Table 4) . A lower number of immunoreactivity of Ser473 phosphorylation only was detected in 5/43 (11.6%) tumour tissues. Statistical analysis showed that the Akt phosphorylation groups were significantly associated with p-BAD (Ser136) (P=0.032) ( Table 4) . By using the Mann-Whitney's U-test, the group with phosphorylated Akt on both sites or Ser473 only had significantly higher level of p-BAD (Ser136) immunoreactivity (P=0.033 or P=0.018, respectively), compared to the group with non-phosphorylated Akt (Table 4) . This relationship was not observed with ER-α, HER2 or Ki-67.
Association of the Expression of Biomolecules with Clinicopathological Features
Statistical analysis of the association of biomolecules with the clinicopathological features (listed in Table 1) showed that the p-Akt (Ser473) immunoreactivity was significantly higher in stage IV than in stage I or II (P=0.036 or P=0.009, respectively; Fig. 3a) . Furthermore, we observed that the Ki-67 expression was significantly associated with patient age of <50 years (P=0.004; Fig. 3b ). In addition, patients with lymph node metastases tended to have a lower ER-α expression (P=0.033; Fig. 3c ). No significant association of other biomolecules with the clinicopathological features was found (data not shown).
Discussion
Immunohistochemical analysis of ER-α and HER2 has become a standard of care for breast cancer patients. The presence of nuclear ER-α and membrane HER2 correlates with increased likelihood of response to antioestrogen and anti-HER2 therapy, respectively. The difficulties encountered in immunohistochemical studies include subjectivity of scoring, choice of source of primary antibody, length and type of fixatives, antigen retrieval methods and cut-off values to determine positivity. Our study showed a lower percentage of ER-α positivity compared to 50-80% in previous studies [28] . However, our data with anti-ER-α (clone F-10 from Santa Cruz) was similar to an ER-α immunopositivity of 21% from a previous study from Malaysia [29] . Monoclonal antibody F-10 binds to the Cterminus of ER-α. Looi et al. [29] used a monoclonal antibody, ER1D5 from Dako which detects the N-terminus of ER-α. All splice variants will also be positive with these two antibodies [30, 31] . It is unclear whether the lower rates of ER-α could be due to age as highest proportion of ER-α positive cases are in the age group of >65 [32] . In our study, about half of the samples (21/43) were ≥50 years of age and only 6/43 (14%) was aged >65. Overexpression of HER2 has been reported in 25-30% of invasive breast cancer [33] . Our data shows that HER2 positivity rate was high (51.2%) consistent with positivity rate of 44% from a previous Malaysian study [29] . These two Malaysian studies show that a relatively high percentage of breast tumour samples are HER2 positive. We noted that a lower proportion of specimens used in this study were ER-α + HER2
+ [9/43 (20.9%)] in contrast to 33.3% in the previous study [29] . However, our data show an inverse correlation between HER2 and ER-α expression, which supports the findings reported by others [34, 35] . Moreover, as previously reported [36, 37] , we found a negative correlation of ER-α with the proliferation marker, Ki-67, suggestive of more aggressive behaviour of breast cancer with less or no ER-α expression. Indeed, a ras superfamily gene has been identified to be up-regulated by ER and able to suppress growth of breast cancer cells [38] . A previous study [39] showed that the ER-α status is determined by the activity of Forkhead box protein FOXO3a, which plays a critical role in cell death and cell cycle arrest and therefore may also explain the finding of inverse correlation between proliferation and ER-α expression.
We observed that there was a lower positivity of ER-β (3/43, 7.0%) in the present study compared to that of Fuqua et al. [40] (76%) and Skliris et al. [41] (79%), which used the same antibody clone (14C8) and scoring system (Allred) with ours. However, a difference between these studies was the cut-off point for determination of ER-β positivity. Fuqua et al. [40] and our studies used a value greater than 2, whereas Skliris et al. [41] used a value greater than 4. The low frequency of ER-β in our study may be explained by differences in the size, ethic and clinicopathological background of the breast cancer cohort. We noted that the ER-β level tended to be lower in breast cancers (7.0%) than apparently normal adjacent breast tissues (7/13, 53.8%; data not shown). It has been hypothesized that the progressive loss of ER-β may lead to abnormal cellular proliferation and/or transformation, thus impacting the process of carcinogenesis in breast cancer [42] . In contrast to a study by Al-Bazz et al. [43] , our analysis of the relationship between Akt phosphorylation and oestrogen receptor status showed no correlation of p-Akt (Ser473) or p-Akt (Thr308) expression with ER-α or ER-β. Our data suggest that Akt phosphorylation in breast cancer could occur independently from the activity of ER-α. This is consistent with a previous tissue microarray study on 285 cases [44] and also with the in vitro studies, whereby, oestrogen can increase Akt activation in ER-α positive [45] and negative [46] breast cancer cell lines. Conversely, Akt activation was reported to be linked to activation of ER-α, via phosphorylation, in tamoxifen-treated ER-α-positive breast cancers [47] .
HER2, also known as c-erbB-2 or neu, is a member of the Type 1 tyrosine kinase growth factor receptor family. It forms heterodimers with other members of its receptor family, such as epidermal growth factor receptor (EGFR/ c-erbB-1) and responds to circulating ligands (e.g. epidermal growth factor) to generate the intracellular signal transduction involving multiple proto-oncogene products such as protein kinase C, phosphatidylinositol 3-kinase (PI3K), and Akt kinase [48] . Their constitutive activation occurs as a consequence of overexpression of HER2 [49, 50] and may be sufficient to cause transformation [51] . In the present study, no relationship between p-Akt (Thr308) or (Ser473) and HER2 was found and this is consistent with the previous reports [44, 52] . In contrast, a positive correlation of phosphorylated Akt with HER2 overexpression [53] [54] [55] and activation via phosphorylation [47] was reported suggesting that HER2 is an upstream regulator of the Akt signaling in breast cancer.
The inhibition of apoptosis and promotion of cell proliferation, angiogenesis and metastasis are key processes in the development of various malignancies. Akt, a serine/ threonine kinase has emerged as an essential mediator of these biological processes [56] . For example, activated Akt phosphorylates BAD at Ser136 which results in its association with 14-3-3 proteins, and thus preventing p-BAD from interacting with Bcl-2 or Bcl-xL and subsequent apoptosis [57] . In a recent study, there was no association between p-Akt level and BAD expression but a significant correlation was found between expression of Akt and BAD [43] . However, the phosphorylation of BAD, indicating of inactivation, was not reported in that study. In the present study, we found a significant correlation of p-Akt (Ser473) with increased level of p-BAD (Ser136). Although the phosphorylation of Akt on both Ser473 and Thr308 has been shown to be required for full activation of the kinase [16, 27] , we found no difference between co-phosphorylated Akt and only one of these residues in phosphorylation of the downstream target, BAD. However, we observed that the level of p-BAD (Ser136) is significantly higher in tumours with Akt phosphorylation at both sites or Ser473 only than those that express none of them (Table 4 ). These findings suggest a possible role of Akt activation in phosphorylation and inactivation of BAD, thus promoting cell survival in breast cancer. In concordance with an in vitro study, inactivation of BAD through ERK (extracellular-regulated kinase) and Akt signaling pathways can abrogate apoptosis of a breast cancer cell line, MCF-7 [58] . We found no correlation between p-Akt and Ki-67 expression although the activation of PI3K/Akt pathway through HER2 is known to increase cell growth and survival [59] .
Analysis of the association of biomolecules with clinicopathological features showed that the p-Akt (Ser473) level was significantly elevated in stage IV breast cancer compared to stage I and II (Fig. 3a) , which is consistent with a previous report [60] . In a study of trastuzumab-containing neo-adjuvant chemotherapy, however, p-Akt was not associated with the clinical outcome [61] . Moreover, our data showed that the Ki-67 expression was higher in younger (<50 years) breast cancer patients, which is in agreement with the published reports [62, 63] . Unlike reported data that show lack of association between ER-α expression and lymph node status [34, 35] , however, Hussein et al. [64] and we found a significantly lower ER-α level in positive nodal status than negative status in our breast cancer cases. Taken together, these findings suggest increased p-Akt (Ser473) level, lower age and reduced/negative ER-α expression are markers for aggressive clinical behavior in breast cancer patients.
In conclusion, our study shows that a higher number of breast tumours were HER2 positive (53.5%) compared to ER-α positive (41.9%). Only 7.0% of the tumours expressed ER-β. In this study, we distinguished the phosphorylation status of Akt at amino acid residue Ser473 and Thr308. No correlation of p-Akt (Ser473) or p-Akt (Thr308) with HER2 or ER-α was found. Our data shows clearly that there was a positive correlation between p-Akt (Ser473) level and the phosphorylation of downstream target, BAD suggesting a role of Akt pathway in inhibition of apoptosis and ultimately, leads to survival of the tumour. The increase of p-Akt (Ser473) level, as well as lower ER-α expression, was associated with more aggressive tumours. This study provides information on alterations of these molecules which may involve in the mechanisms that underlie breast carcinogenesis. We are aware that the sample size was relatively small and therefore, data need to be further investigated with larger sample size. Taken collectively, we suggest that Akt is a relevant target in a reasonable proportion of our Malaysian patients. However, further elucidation of the significance of Akt activation in clinical outcome is needed to provide more useful information about treatment strategy for breast cancer patients.
